Cancer associated myositis (CAM): clinical features
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Cancer associated myositis (CAM): clinical features. This is the occurrence of cancer with myositis within a 3-year period.
Definition
- This is the occurrence of cancer with myositis within a 3-year period
Frequent associated cancers
Locked: subscribe to see this section.
Major risky antibodies
Locked: subscribe to see this section.
Occasional risky antibodies
Locked: subscribe to see this section.
Risk phenotypes
Locked: subscribe to see this section.
Risky clinical features
Locked: subscribe to see this section.
Clinical features of TIF-γ CAM
Locked: subscribe to see this section.
Clinical features of NXP2 CAM
Locked: subscribe to see this section.
Clinical features of P155 CAM
Locked: subscribe to see this section.
Acronyms
Locked: subscribe to see this section.
References
- Masiak A, Kulczycka J, Czuszyńska Z, Zdrojewski Z. Clinical characteristics of patients with anti-TIF1-γ antibodies. Reumatologia 2016; 54:14-18.
- Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology 2016; 87:299-308.
- Selva-O'Callaghan A, Trallero-Araguás E, Ros J, et al. Management of cancer-associated myositis. Curr Treatm Opt Rheumatol 2022; 8:91-104.
- Fayyaz B, Rehman HJ, Uqdah H. Cancer-associated myositis: an elusive entity. J Community Hosp Intern Med Perspect 2019; 9:45-49.
- Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009; 34:561-565.
- And 13 more. Subscribe to see the full list
